David Bennett, MD
Nephrology · Trumbull, CTNPI 1326337940
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $772 of the $893 with a category attached, or 86.5%. 15 manufacturers reported payments, led by AstraZeneca at 34.1% of the total. Reporting peaked in 2019 at $287 and has fallen 65.6% since, to $99 in 2025.
Across 43 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$304
- Apellis Pharmaceuticals, Inc.$101
- Vifor Pharma, Inc.$77
- Amgen$68
- Bayer$60
- Ardelyx, Inc.$54
- plus $229 from 9 others
Across 71 payments — averaging $153.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$11K
What the payments were for
- Food & beverage$77286%
- Education$12114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $304 |
| Apellis Pharmaceuticals, Inc. | 1 | $101 |
| Vifor Pharma, Inc. | 4 | $77 |
| Amgen | 3 | $68 |
| Bayer | 2 | $60 |
| Ardelyx, Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Baxter Healthcare | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $28 |
| Travere Therapeutics, Inc. | 6 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
How this compares
$893 in reported general payments places this provider in the 55th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 28 | $80,168 |
| LokelmaSodium Zirconium Cyclosilicate | 59 | $50,557 |
| Sevelamer Carbonate | 58 | $9,274 |
| FarxigaDapagliflozin Propanediol | 13 | $8,388 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $7,909 |
| Potassium Chloride | 20 | $3,490 |
| Calcitriol | 66 | $1,731 |
| Calcium Acetate | 12 | $1,076 |
| Midodrine Hcl | 19 | $833 |
| Amlodipine Besylate | 78 | $792 |
| Losartan Potassium | 50 | $492 |
| Hydralazine Hcl | 31 | $478 |
| Furosemide | 64 | $400 |
| Carvedilol | 34 | $236 |
| Spironolactone | 18 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma, Farxiga | $304 | $58,94572 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 144 nephrology providers in Connecticut.
Other nephrology in Trumbull
- James GavinTrumbull$103K
- Aaron DommuTrumbull$1K
- Robert AlpernNew Haven$4.9M
- Ari GellerBloomfield$209K
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- David SimonOrange$59K
- Ladan GolestanehNew Haven$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.